by John A. Jenkins | Jul 17, 2024 | FOIA, Law Firms, SEC, Stock Market
The American Securities Association Uses a FOIA Lawsuit to Advance Its Agenda Two months ago, the two Republican members of the Securities and Exchange Commission blasted their own agency for what they called a meritless prosecution of stock exchanges. In a blunt...
by Randy E. Miller | May 30, 2024 | FDA, FOIA, Hedge Funds, News Media, Pharmaceuticals, Stock Market
FOIAengine: Requests Show FDA Still Under Pressure This week, we’re taking a closer look at the numerous Freedom of Information Act requests recently filed with the Food and Drug Administration concerning the problematic India pharmaceutical industry. As we noted in...
by John A. Jenkins | Apr 30, 2024 | FOIA, Hedge Funds, Stock Market
FOIAengine: Traders Had an Inside Track on the CPI. Journalists Used FOIA to Expose It. Today’s story is about the Bureau of Labor Statistics, which calculates the all-important Consumer Price Index. It’s also a cautionary tale about how a select few on Wall Street...
by Randy E. Miller | Mar 27, 2024 | FDA, FOIA, Hedge Funds, Law Firms, Litigation, Non-Profits, Pharmaceuticals, Politics, Short-Selling, Stock Market
FOIAengine: Conservative Activists, Law Firms, Non-Profits Signal Competing Agendas A review of the most recent Freedom of Information Act requests made to the Food and Drug Administration illustrates how political organizations, law firms, news media, and financial...
by John A. Jenkins | Mar 6, 2024 | FOIA, Litigation, Short-Selling, Stock Market
FOIAengine Previews an April Fool’s Day Courtrooom Grudge Match This week’s story is about two litigation magnets. One is a household name whose lawsuit against OpenAI dominated the news a few days ago. That would be Elon Musk. The other – Aaron Greenspan –...
by Randy E. Miller | Feb 14, 2024 | FDA, FOIA, Hedge Funds, Litigation, Pharmaceuticals, Short-Selling, Stock Market
FOIAengine Breaks Down the Action Financial firms are continuing to monitor many of the pharmaceutical manufacturers we’ve reported on in recent months, including Krystal Biotech, Apellis Pharmaceuticals, Establishment Labs, Catalent and Astellas. That’s according to...
